Status:

COMPLETED

A Study of Percutaneous Repair of Functional Mitral Regurgitation Using the Ancora Heart, Inc. AccuCinch® Ventricular Repair System - The CINCH-2 Study

Lead Sponsor:

Ancora Heart, Inc.

Conditions:

Mitral Regurgitation

Mitral Valve Regurgitation

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Prospective single-arm study of the AccuCinch® Ventriculoplasty System in the treatment of mitral valve regurgitation through subvalvular mitral repair. Purpose: To demonstrate the safety, feasibilit...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years
  • Severity of FMR: ≥ Moderate (i.e., 2+)
  • Ejection Fraction: ≥ 20% to ≤60%
  • Symptom Status: NYHA II-IVa
  • Treatment and compliance with optimal guideline directed medical therapy for heart failure for at least 1 month
  • Surgical risk: Subject is eligible for cardiac surgery (specific EuroSCORE (LES or ESII), STS, or comorbidities should demonstrate high risk features)
  • Completion of all qualifying diagnostic and functional tests and agrees to comply with study follow-up schedule

Exclusion

  • Significant organic mitral valve pathology (e.g. myxomatous degeneration, mitral valve prolapse or flail leaflets)
  • Myocardial infarction or any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days
  • Prior surgical, transcatheter, or percutaneous mitral valve intervention
  • Untreated clinically significant coronary artery disease (CAD) requiring revasularization
  • Hemodynamic instability: Hypotension (systolic pressure \<90 mmHg) or requirement for inotropic support or mechanical hemodynamic support
  • Any planned cardiac surgery within the next 6 months (including right heart procedures)
  • NYHA class (i.e., non-ambulatory) or ACC/AHA Stage D heart failure
  • Fixed pulmonary artery systolic pressure \>70 mmHg
  • Severe tricuspid regurgitation (per ASE guidelines and graded by the Echo Core Lab)
  • Modified Rankin Scale ≥ 4 disability
  • Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology
  • Mitral valve area less than 4.0 cm2
  • Anatomical pathology/contraints preventing appropriate access/ implant of the AccuCinch System
  • Renal insufficiency (i.e., eGFR of \<30ml/min/1.73m2 ; Stage 4 or 5 CKD)
  • Moderate or severe aortic valve stenosis or regurgitation or aortic valve prosthesis Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile aortic atheroma, intracardiac mass, thrombus or vegetation
  • Active bacterial endocarditis
  • History of stroke within the prior 3 months
  • Subjects in whom anticoagulation or antiplatelet therapy is contraindicated
  • Known allergy to nitinol, polyester, or polyethylene
  • Any prior true anaphylactic reaction to contrast agents; defined as known anaphylactoid or other non-anaphylactic allergic reactions to contrast agents that cannot be adequately pre-medicated prior to the index procedure.
  • Life expectancy \< 1 year due to non-cardiac conditions
  • Currently participating in another interventional investigational study
  • Implant or revision of any rhythm management device (CRT or CRTD) or implantable cardioverter defibrillator within 1 month
  • Absence of CRT with class I indication criteria for biventricular pacing (left bundle branch block pattern and QRS duration ≥150 ms)
  • On high dose steroids or immunosuppressant therapy
  • Female subjects who are pregnant or lactating

Key Trial Info

Start Date :

November 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2021

Estimated Enrollment :

16 Patients enrolled

Trial Details

Trial ID

NCT00800046

Start Date

November 1 2008

End Date

January 1 2021

Last Update

July 29 2021

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

Medical University of Vienna

Vienna, Austria

2

University Hospital Freiburg-Bad Krozingen

Bad Krozingen, Germany

3

Immanuel Klinikum Bernau Herzzentrum Brandenburg

Bernau, Germany

4

St.-Johannes-Hospital

Dortmund, Germany

A Study of Percutaneous Repair of Functional Mitral Regurgitation Using the Ancora Heart, Inc. AccuCinch® Ventricular Repair System - The CINCH-2 Study | DecenTrialz